• Explore /
  • Poster
  • / Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.

Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.

Abstract Poster

Authors

null

Christophe Tournigand

Hopital Henri Mondor, UPEC, Creteil, France

Christophe Tournigand , Benoist Chibaudel , Benoit Samson , Werner Scheithauer , Gérard Lledo , Pascal Artru , Frédéric Viret , Jean-Francois RAMEE , Nicole Tubiana-Mathieu , Jérôme Dauba , Olivier Dupuis , Yves Rinaldi , May Mabro , Nathalie Aucoin , Franck Bonnetain , Christophe Louvet , Annette K. Larsen , Thierry André , Aimery De Gramont

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00265824

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 670)

DOI

10.1200/jco.2015.33.3_suppl.670

Abstract #

670

Poster Bd #

D12

Abstract Disclosures

Similar Posters

First Author: Carlos Alberto Mayo

First Author: Kei Muro

First Author: Johanna C. Bendell

First Author: Christophe Tournigand